11099 Torrey Pines Park Road
About Fortis Therapeutics
Fortis Therapeutics is an immuno-oncology biotech focused on developing new antibody drug conjugate therapies for late-stage multiple myeloma and late-stage prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D. The company's investors are Avalon Ventures, Bregua Corporation, Lilly Asia Ventures, Osage University Partners, and Vivo Capital. Fortis Therapeutics is located in COI Pharmaceuticals, Avalon's Community of Innovation, in San Diego.
President and CEO: Jay Lichter, Ph.D
CSO: Marc Nasoff, Ph.D.
CFO: Tighe Reardon
Principal Scientist: Joshua Park, Ph.D.
3 articles with Fortis Therapeutics
Fortis Therapeutics is focused on immuno-oncology, specifically on developing an ADC for multiple myeloma and late-stage prostate cancer, including both the adenocarcinoma and neuroendocrine types.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.